GMKBCaitlin G. Allen, Kelly J. Hunt, Lori L. McMahon, Clay Thornhill, Amy Jackson, John T. Clark, Katie Kirchoff, Kelli L. Garrison, Kimberly Foil, Libby Malphrus, Samantha Norman, Paula S. Ramos, Kelly Perritt, Caroline Brown, Leslie Lenert, and Daniel P. Judge.
Precision Medicine and Immunotherapy: The new frontiers in cancer care?
Precision Medicine and Immunotherapy: The new frontiers in cancer care?
Friday, November 10 | 11 a.m. ET | Online
Speaker: Ugwuji Maduekwe, MD, MMSc, MPH
Dr. Maduekwe will present an exploration of the dispersion of new therapies in the care of cancer that are inequitably distributed and solutions to closing these gaps.
To learn more and register, visit the webinar page.
Please note: Registration for the full webinar series is required.
Translating Science from Bench to Bedside: A Case for Extracellular Vesicles
Translating Science from Bench to Bedside: A Case for Extracellular Vesicles
Thursday, February 29 | 9 a.m. ET | Online
Speaker: Dr. Carlos Salomon Gallo
Dr. Salomon is the head of the Translational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group, NHMRC Investigator Fellow and is considered a worldwide authority on extracellular vesicles (EVs) biomarkers for complications of pregnancies and ovarian cancer (OC). In the last 10 years, Dr. Salomon’s primary research and commercialization activities have focused on the identification and validation of biomarkers, and development of In Vitro Multivariate Index Assays for clinically relevant complications (including ovarian cancers, and obstetrical syndromes) and their translation into clinical applications. He is a pioneer in investigating the release of EVs by the placenta and tumor cells and their utility as a biomarker for a wide range of pregnancy complications and OC.
This talk will cover the burgeoning field of EVs signaling holds the potential to revolutionize our understanding of cancer biology and offers new avenues for non-invasive diagnostics and therapeutic interventions. EVs have been implicated in various aspects of cancer progression, including tumor initiation, metastasis, and response to therapy. From the early stages of tumor development, tumor-derived EVs are detectable in the circulation.
To learn more and register, visit the GGMC Educational Webinar Series webpage.
Please note: Registration is required for this webinar.
Incorporating Integrated Diagnostics into Precision Oncology Care: A Workshop
Monday, March 6 – Tuesday, March 7 | Washington, DC & Virtual
Innovations in the diagnostic specialties have the potential to dramatically reshape cancer diagnosis and enable precision therapy. Spurred by advances in informatics, there are opportunities to combine and collate information from imaging, pathology, and molecular testing. Multidisciplinary collaboration among pathologists, radiologists, and oncologists—supplemented by machine-learning based tools—could facilitate a more precise understanding of a patient’s diagnosis and what treatment strategies may be most effective for improved patient outcomes. Integrated diagnostics also have the potential to improve patient access to subspecialty expertise, particularly in community-based settings of cancer care.
This National Academies workshop, convened by the National Cancer Policy Forum, in collaboration with the Academies’ Computer Science and Telecommunications Board, and the Board on Human-Systems Integration, is an opportunity for the cancer community to better define the purpose, goals, and components of integrated diagnostics. Workshop presentations and discussions will examine the current state of integrated diagnostics in facilitating precision cancer care and highlight speaker perspectives on the vision for the future.
Visit the event page on the National Academies website for more details and to register.
Assessment of the Clinical Utility of Pretreatment DPYD Testing for Patients Receiving Fluoropyrimidine Chemotherapy
Daniel L. Hertz
Abstract
Purpose: Patients who carry pathogenic variants in DPYD have higher systemic fluoropyrimidine (FP) concentrations and greater risk of severe and fatal FP toxicity. Pretreatment DPYD testing and DPYD-guided FP dosing to reduce toxicity and health care costs is recommended by European clinical oncology guidelines and has been adopted across Europe, but has not been recommended or adopted in the United States. The cochairs of the National Comprehensive Cancer Network Guidelines for colon cancer treatment explained their concerns with recommending pretreatment DPYD testing, particularly the risk that reduced FP doses in DPYD carriers may reduce treatment efficacy.
- PMID: 36108264
- DOI: 10.1200/JCO.22.00037
- Article on PubMed.gov
ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series
Tuesday, September 27, 2022 | 11 am – 12 pm ET | Virtual
Therapy-related neoplasms are recognized as a late effect of genotoxic exposure (cytotoxic chemotherapy or irradiation as a treatment for primary malignancy) or complication after solid organ transplant or treatment of autoimmune disorder. The importance of recognition of this type of neoplasms in oncology testing will be discussed in this session through a series of representative cases. These illustrative cases will demonstrate the utility of various axillary testing types in identification of markers associated with specific prognosis in this type of cancer and treatment options.
This workshop is for all medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and the ACMG consortia.
Learn more and register on the American College of Medical Genetics and Genomics website.